بدائل البحث:
marked decrease » marked increase (توسيع البحث)
marker decrease » larger decrease (توسيع البحث), marked increase (توسيع البحث), markedly decreased (توسيع البحث)
lasso decrease » largest decrease (توسيع البحث)
i marked » _ marked (توسيع البحث), _ market (توسيع البحث), _ marker (توسيع البحث)
a marker » _ marker (توسيع البحث), _ markers (توسيع البحث)
marked decrease » marked increase (توسيع البحث)
marker decrease » larger decrease (توسيع البحث), marked increase (توسيع البحث), markedly decreased (توسيع البحث)
lasso decrease » largest decrease (توسيع البحث)
i marked » _ marked (توسيع البحث), _ market (توسيع البحث), _ marker (توسيع البحث)
a marker » _ marker (توسيع البحث), _ markers (توسيع البحث)
-
1
-
2
-
3
-
4
Evogliptin attenuates the pyroptotic cell death of VSMCs during CER treatment by decreasing the pyroptotic-associated genes and GSDM-D cleavage efficiency <i>in-vitro.</i>
منشور في 2025"…<p>(A) Bar graph showed EVO significantly decreased Lactate dehydrogenase (LDH) release in CER treated P<sub>i</sub>‐induced VSMCs. …"
-
5
-
6
-
7
-
8
-
9
-
10
-
11
Table 5_Immune-related diagnostic indicators and targeted therapies for COPD combined with NASH were identified and verified via WGCNA and LASSO.xlsx
منشور في 2025"…These findings suggest that S100A9 serves as a common inflammatory marker for both diseases, whereas MYH2 may be regulated by disease-specific mechanisms, highlighting its potential for distinguishing COPD from NAFLD.…"
-
12
Table 1_Immune-related diagnostic indicators and targeted therapies for COPD combined with NASH were identified and verified via WGCNA and LASSO.xlsx
منشور في 2025"…These findings suggest that S100A9 serves as a common inflammatory marker for both diseases, whereas MYH2 may be regulated by disease-specific mechanisms, highlighting its potential for distinguishing COPD from NAFLD.…"
-
13
Table 4_Immune-related diagnostic indicators and targeted therapies for COPD combined with NASH were identified and verified via WGCNA and LASSO.xlsx
منشور في 2025"…These findings suggest that S100A9 serves as a common inflammatory marker for both diseases, whereas MYH2 may be regulated by disease-specific mechanisms, highlighting its potential for distinguishing COPD from NAFLD.…"
-
14
Table 3_Immune-related diagnostic indicators and targeted therapies for COPD combined with NASH were identified and verified via WGCNA and LASSO.xlsx
منشور في 2025"…These findings suggest that S100A9 serves as a common inflammatory marker for both diseases, whereas MYH2 may be regulated by disease-specific mechanisms, highlighting its potential for distinguishing COPD from NAFLD.…"
-
15
Table 6_Immune-related diagnostic indicators and targeted therapies for COPD combined with NASH were identified and verified via WGCNA and LASSO.xlsx
منشور في 2025"…These findings suggest that S100A9 serves as a common inflammatory marker for both diseases, whereas MYH2 may be regulated by disease-specific mechanisms, highlighting its potential for distinguishing COPD from NAFLD.…"
-
16
Table 2_Immune-related diagnostic indicators and targeted therapies for COPD combined with NASH were identified and verified via WGCNA and LASSO.xlsx
منشور في 2025"…These findings suggest that S100A9 serves as a common inflammatory marker for both diseases, whereas MYH2 may be regulated by disease-specific mechanisms, highlighting its potential for distinguishing COPD from NAFLD.…"
-
17
-
18
-
19
-
20